Neutrophils modulate post-thrombotic vein wall remodeling but not thrombus neovascularization

Summary

Early deep venous thrombosis (DVT) resolution is associated with neutrophil (PMN) influx. This study examined the role of PMNs in thrombus neovascularization and vein wall injury after DVT. A rat model of DVT by inferior vena cava (IVC) ligation was performed with control serum or rabbit anti-rat PMN serum administered perioperatively with sacrifice at 2 and 7 days. At 2 days, neutropenic rats had 1.6-fold larger thrombi (P = .04) and 1.4-fold higher femoral venous pressures by water manometry (P = .008) but no difference in thrombus neovascularization was observed. By7 days, DVT sizes were similar, but vein wall injury persisted in the neutropenic rats with a 2.0-fold increase in vein wall stiffness by microtensiometry (P< .05), as well asa 1.2-fold increased thickness (P = .04). Collagen and profibrotic growth factors were significantly increased in neutropenic IVC at7 days (all P< .05).Vein wall and intrathrombus uPA by Western immunoblotting, and intrathrombus MMP-9 gelatinase activity were significantly less in neutropenic rats than controls (P < .001). Conversely, MMP-2 was significantly elevated in neutropenic IVC at 2 days after DVT. However, neutropenia induced 24 hours after DVT formation resulted in no significant increase in vein wall stiffness or collagen levels at 7 days, despite 1.4-fold larger thrombi (P < .05). These data suggest a critical early role for PMN in post DVT vein wall remodeling.

Keywords

Animal models - tissue remodelling - leukocyte function / activation - deep vein thrombosis

* Presented in part at the 65^th Annual Meeting of the Society of University Surgeons, February 13, 2004, St. Louis, MO, USA.

• References

• 1 Prandoni P, Lensing AW, Cogo A. et al. The longterm clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
• 2 Henke PK, DeBrunye LA, Strieter RM. et al. Viral IL-10 Gene Transfer Decreases Inflammation and Cell Adhesion Molecule Expression in a Rat Model of Venous Thrombosis. J Immunol 2000; 164: 2131-41.
• 3 Henke PK, Wakefield TW, Kadell AM. et al. Interleukin-8 administration enhances venous thrombosis resolution ina rat model. J Surg Res 2001; 99: 84-91.
• 4 Wakefield TW, Linn MJ, Henke PK. et al. Neovascularization during venous thrombosis organization: A preliminary study. J Vasc Surg 1999; 30: 885-93.
• 5 Stewart GJ. Neutrophils and deep venous thrombosis. Haemostasis 1993; 23 (Suppl. 01) 127-40.
• 6 Henke PK, Varga A, De S. et al. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity ina mouse model. Arterioscler Thromb Vasc Biol 2004; 24: 1130-7.
• 7 Varma MR, Moaveni DM, Dewyer NA. et al. Deep vein thrombosis resolution is not accelerated with increased neovascularization. J Vasc Surg 2004; 40: 536-42.
• 8 Thanaporn P, Myers DD, Wrobleski SK. et al. P-selectin inhibition decreases post-thrombotic vein wall fibrosis in a rat model. Surgery 2003; 134: 365-71.
• 9 Varma MR, Varga AJ, Knipp BS. et al. Neutropenia impairs venous thrombosis resolution in the rat. J Vasc Surg 2003; 38: 1090-8.
• 10 Moir E, Booth NA, Bennett B. et al. Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism. Br J Haematol 2001; 113: 72-80.
• 11 Singh I, Burnand KG, Collins M. et al. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation 2003; 107: 869-75.
• 12 McCourt M, Wang JH, Sookhai S. et al. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 1999; 134: 1325-31 discussion 1331-2.
• 13 Singer AJ, Clark RA. Cutaneous wound healing. N EnglJ Med 1999; 341: 738-46.
• 14 Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39.
• 15 Myers Jr DD, Henke PK, Wrobleski SK. et al. P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model. J Vasc Surg 2002; 36: 928-38.
• 16 Couffinhal T, Silver M, Kearney M. et al. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE−/−mice. Circulation 1999; 99: 3188-98.
• 17 Franz MG, Smith PD, Wachtel TL. et al. Fascial incisions heal faster than skin: A new model of abdominal wall repair. Surgery 2001; 129: 203-8.
• 18 Upchurch GR, Ford JW, Weiss SJ. et al. Nitric oxide inhibition increases matrix metalloproteinase-9 expression bya rat aortic smooth muscle cells in vitro. J Vasc Surg 2001; 34: 76-83.
• 19 Forsberg E, Kjellen L. Heparan sulfate: lessons from knockout mice. J Clin Invest 2001; 108: 175-80.
• 20 Schafer K, Konstantinides S, Riedel C. et al. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase-or tissuetype plasminogen activator. Circulation 2002; 106: 1847-52.
• 21 Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42.
• 22 See-Tho K, Harris Jr EJ. Thrombosis with outflow obstruction delays thrombolysis and results in chronic wall thickening of rat veins. J Vasc Surg 1998; 28: 115-22 discussion 123.
• 23 Zhang G, Kim H, Cai X. et al. Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy. J Am Soc Nephrol 2003; 14: 1234-53.
• 24 Chou DH-I, Lee W, McCulloch CA. TNFa inactivation of collagen receptors. J Immunol 1996; 156: 4354-62.
• 25 Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol 2001; 69: 513-21.
• 26 Whatling C, McPheat W, Hurt-Camejo E. Matrix management: Assigning different roles for MMP-2 and MMP-9 in vascular remodeling. Arterioscler Thromb Vasc Biol 2004; 24: 10-11.
• 27 Tran PK, Tran-Lundmark K, Soininen R. et al. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfatedeficient perlecan. Circ Res 2004; 94: 550-8.
• 28 Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 1991; 12: 17-23.
• 29 Grainger DJ, Wakefield L, Bethell HW. et al. Release and activation of platelet latent TGFb in blood clots during dissolution with plasmin. Nature Med 1995; 01: 932-7.
• 30 Dovi JV, He LK, DiPietro LA. Accelerated wound closure in neutrophil-depleted mice. J Leukoc Biol 2003; 73: 448-55.
• 31 Sunderkotter C, Steinbrink K, Goebeler M. et al. Macrophages and angiogenesis. J Leukoc Biol 1994; 55: 410-22.
• 32 Lin J, Proctor MC, Varma M. et al. Factors associated with recurrent venous thromboembolism in patients with malignant disease. J Vasc Surg 2003; 37: 976-83.
• 33 Wakefield TW. Treatment options for venous thrombosis. J Vasc Surg 2000; 31: 613-20.